Studies found that the selective intestinal FXR agonist fexaramine could improve obesity-related metabolic dysfunctions, and activate G protein-coupled bile acid receptor 1/Glucagon-like peptide-1 signaling to improve insulin sensitivity and increase adipose tissue browning (Jiang et al., 2015). The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.